Friday, July 10, 2026

pharma · Thyroid eye disease · Thyroid Eye Disease · VRDN

Viridian Pharma

Viridipharm is a pharma organization headquartered in Elmwood Park, USA. It trades on NYSE under ticker VRDN. Primary therapeutic focus areas include Thyroid eye disease, Thyroid Eye Disease, Thyroid eye disease (TED), T

200 Market Street, ELMWOOD PARK, NJ 07407, US HQ
2017 Founded
2 Employees
Public company Type
VRDN · NYSE Ticker
Company details
Clinical program

VRDN-003

Phase 3 · small molecule · Thyroid Eye Disease

VRDN-003 for Thyroid Eye Disease is a Phase 3 program (small_molecule) at Viridian Pharma Ltd with 3 ClinicalTrials.gov record(s).

← All Viridian Pharma Ltd projects Phase 3 small molecule active

Internal code VRDN-003-302

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Viridian Pharma Ltd
Phase
Phase 3
Modality
small_molecule
Indication
Thyroid Eye Disease
Status
active
Trials
3